Compare · ARAY vs DXCM
ARAY vs DXCM
Side-by-side comparison of Accuray Incorporated (ARAY) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARAY and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $23.67B, about 427.0x ARAY ($55.4M).
- Over the past year, ARAY is down 65.8% and DXCM is down 24.8% - DXCM leads by 41.0 points.
- Both names hit the wire about 8 times in the past 4 weeks.
- DXCM has more recent analyst coverage (25 ratings vs 3 for ARAY).
- Company
- Accuray Incorporated
- DexCom Inc.
- Price
- $0.47+0.71%
- $61.33+3.02%
- Market cap
- $55.4M
- $23.67B
- 1M return
- +19.77%
- -1.65%
- 1Y return
- -65.82%
- -24.81%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2007
- 2005
- News (4w)
- 8
- 8
- Recent ratings
- 3
- 25
Accuray Incorporated
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, including the Radixact System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest ARAY
- Accuray Incorporated filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Accuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026
- Amendment: SEC Form SCHEDULE 13D/A filed by Accuray Incorporated
- SEC Form 3 filed by new insider Tcw Group Inc
- SEC Form 3 filed by new insider Miele Paul Michael
- Accuray Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Accuray Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer
- SEC Form 4 filed by Chalke Sandeep
- Amendment: SEC Form SCHEDULE 13G/A filed by Accuray Incorporated
Latest DXCM
- SEC Form 10-Q filed by DexCom Inc.
- DexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Dexcom Reports First Quarter 2026 Financial Results
- Why Medtech Giants Are Quietly Paying Up for AI Diagnostics
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.